Demographic Characteristics of NVUGIB Patients
Characteristic | Control ( |
Intervention ( |
Total ( |
|
---|---|---|---|---|
Age | 0.056 | |||
Mean (SD) | 53.4 (14.3) | |||
Median | 55.5 | |||
<40 | 7 (21.9) | 6 (18.8) | 13 (20.3) | |
40–<60 | 9 (28.1) | 18 (56.3) | 27 (42.2) | |
60–<80 | 16 (50.0) | 8 (25.0) | 24 (37.5) | |
Sex | 0.412 | |||
Male | 21 (65.6) | 24 (75.0) | 45 (70.3) | |
Female | 11 (34.4) | 8 (25.0) | 19 (29.7) | |
Comorbidities† | 0.095 | |||
No comorbidities | 3 (9.4) | 1 (3.1) | 4 (6.3) | |
Minor | 23 (71.9) | 19 (59.4) | 42 (65.6) | |
Major | 6 (18.8) | 12 (37.5) | 18 (28.1) | |
Anticoagulant use | 0.516 | |||
(–) | 30 (93.8) | 31 (96.9) | 61 (95.3) | |
(+) | 2 (6.3) | 1 (3.1) | 3 (4.7) | |
NSAID use | 0.033* | |||
(–) | 28 (87.5) | 32 (100.0) | 60 (93.8) | |
(+) | 4 (12.5) | 0 (0.0) | 4 (6.2) | |
Hemorrhagic shock | 0.076 | |||
(–) | 22 (68.8) | 14 (43.8) | 36 (56.2) | |
(+) | 10 (31.3) | 18 (56.3) | 28 (43.8) | |
Hemoglobin pre-hemostasis | 0.633 | |||
< 7 g/dL | 10 (31.3) | 9 (28.1) | 19 (29.7) | |
≥ 7 g/dL | 22 (68.8) | 23 (71.9) | 45 (70.3) | |
Rockall score | 0.312 | |||
0 | 2 (6.3) | 1 (3.1) | 3 (4.7) | |
1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
2 | 11 (34.4) | 9 (28.6) | 20 (31.3) | |
3 | 9 (28.1) | 5 (15.6) | 14 (21.9) | |
4 | 3 (9.4) | 6 (18.8) | 9 (14.1) | |
5 | 6 (18.8) | 10 (31.3) | 16 (25.0) | |
6 | 1 (3.1) | 1 (3.1) | 2 (3.1) |